Novelion Therapeutics (NASDAQ:NVLN) CEO, Mary Szela, has resigned for personal reasons, effective immediately, and the company has begun a search for a new CEO.
To lead the company until a permanent CEO is appointed, the board has created an interim office of the CEO, consisting of Jeffrey Hackman, Novelion’s COO; Jason Aryeh, chairman of the board; and Mark Corrigan, a director.
The board also has formed a search committee to find a permanent replacement for Ms. Szela.
In a statement, Mr. Aryeh said Novelion’s strategy and mission will continue to focus on supporting access to its marketed therapies for patients globally and pursuing the development of its product portfolio in order to support long-term and sustainable growth.
“The board is confident in its ability to identify a successor who will effectively drive improved growth and shareholder value by reinvigorating the company’s plans in support of our key objectives,” he added.